Information Provided By: 
Fly News Breaks for September 20, 2016
VRX
Sep 20, 2016 | 05:42 EDT
Deutsche Bank analyst Gregg Gilbert reinstated coverage of Valeant Pharmaceuticals with a Hold rating and $30 price target. Potential fines from the numerous investigations into the company are difficult to predict, Gilbert tells investors in a research note. The analyst assumes revenue for Valeant's dermatology business will begin to rebound in the second half of 2016 and into 2017. Before restricting coverage on the name, Deutsche had a Hold rating on the shares.
News For VRX From the Last 2 Days
There are no results for your query VRX
